-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 20th, Telix Pharmaceuticals announced that the FDA approved Illuccix (TLX591-CDx) for the marketing of prostate cancer diagnostic imaging
TLX591-CDx is a diagnostic positron emission tomography (PET) tracer targeting prostate specific membrane antigen (PSMA) based on radionuclide-antibody coupling technology (RDC), suitable for metastatic prostate cancer And the diagnosis of recurrent prostate cancer
The National Comprehensive Cancer Network (National Comprehensive Cancer Network) prostate cancer guidelines (2020 edition) recommends TLX591-CDx as a new PET tracer.
In November 2020, Grand Pharmaceuticals signed a cooperation agreement with Telix, and obtained a number of first in class tumor diagnostics (TLX250-CDx, TLX599-CDx) and treatments (TLX591, TLX250, TLX101), including TLX591-CDx, in one fell swoop The exclusive commercialization rights of global innovative RDC products in Greater China (including Hong Kong, Macau, Taiwan), and the company with the largest number of therapeutic + diagnostic RDC drugs in China
Prostate cancer is one of the most common male cancers.